Researchers
Harris R. Perlman
Summary
This invention relates generally to compositions and methods for treating immune system mediated diseases, such as rheumatoid arthritis (RA). In particular, certain embodiments of the present invention use BH3 mimetic therapy as an efficacious treatment of the effector phase of rheumatoid arthritis or other immune mediated disorders wherein the compositions and methods of the present invention markedly reduce the level of the Bcl-2 antagonist protein Bim present in RA synovial tissue as compared to control patients. Therefore, the present invention involves restoring the function of Bim in order to ameliorate inflammatory arthritis.
Intellectual Property Status
- U.S. patent pending